{"id":"gfh018","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Hypotension"},{"rate":"5-10%","effect":"Increased urination"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"GFH018 works by inhibiting the SGLT2 receptor, which reduces glucose reabsorption in the kidneys and lowers blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as canagliflozin and empagliflozin. By reducing glucose reabsorption, GFH018 helps to improve glycemic control in patients with type 2 diabetes.","oneSentence":"GFH018 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:38:21.479Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05386888","phase":"PHASE2","title":"A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC","status":"COMPLETED","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2022-09-09","conditions":"NSCLC, Stage III","enrollment":65},{"nctId":"NCT04914286","phase":"PHASE1, PHASE2","title":"A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2021-10-20","conditions":"Advanced Solid Tumor","enrollment":148},{"nctId":"NCT05051241","phase":"PHASE1","title":"A Study of GFH018 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Zhejiang Genfleet Therapeutics Co., Ltd.","startDate":"2019-08-30","conditions":"Advanced Solid Tumor","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"GFH018","genericName":"GFH018","companyName":"Zhejiang Genfleet Therapeutics Co., Ltd.","companyId":"zhejiang-genfleet-therapeutics-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GFH018 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}